Patents by Inventor Clotilde Lagier-Tourenne

Clotilde Lagier-Tourenne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for modulating expression of C9ORF72 antisense transcript
    Patent number: 11162096
    Abstract: Disclosed herein are compositions and methods for reducing expression of C9ORF72 antisense transcript in an animal with C9ORF72 antisense transcript specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C9ORF72 antisense transcript specific inhibitors include antisense compounds.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: November 2, 2021
    Assignees: Ionis Pharmaceuticals, Inc, The Regents of the University of California, Ludwig Institute for Cancer
    Inventors: C. Frank Bennett, Frank Rigo, Don W. Cleveland, Clotilde Lagier-Tourenne, John M. Ravits, Michael W. Baughn
  • METHODS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT
    Publication number: 20180142240
    Abstract: Disclosed herein are compositions and methods for reducing expression of C9ORF72 antisense transcript in an animal with C9ORF72 antisense transcript specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C9ORF72 antisense transcript specific inhibitors include antisense compounds.
    Type: Application
    Filed: December 20, 2017
    Publication date: May 24, 2018
    Applicants: Ionis Pharmaceuticals, Inc., The Regents of the University of California, Ludwig Institute for Cancer Research
    Inventors: C. Frank Bennett, Frank Rigo, Don W. Cleveland, Clotilde Lagier-Tourenne, John M. Ravits, Michael W. Baughn
  • Methods for modulating C9ORF72 expression
    Patent number: 9963699
    Abstract: Disclosed herein are methods for reducing expression of C90RF72 mRNA and protein in an animal with C90RF72 specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C90RF72 specific inhibitors include antisense compounds. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration C90RF72 specific inhibitors include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), corticalbasal degeneration syndrome (CBD), atypical Parkinsonian syndrome, and olivopontocerellar degeneration (OPCD).
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: May 8, 2018
    Assignees: Ionis Pharmaceuticals, Inc., Ludwig Institute for Cancer Research, The Regents of the University of California
    Inventors: C. Frank Bennett, Susan M. Freier, Frank Rigo, Don W. Cleveland, Clotilde Lagier-Tourenne, John M. Ravits, Michael W. Baughn
  • METHODS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT
    Publication number: 20160237432
    Abstract: Disclosed herein are methods for reducing expression of C90RF72 antisense transcript in an animal with C90RF72 antisense transcript specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C90RF72 antisense transcript specific inhibitors include antisense compounds.
    Type: Application
    Filed: October 14, 2014
    Publication date: August 18, 2016
    Applicants: Ionis Pharmaceuticals, Inc., The Regents of the University of California, Ludwig Institute For Cancer Research
    Inventors: C. Frank Bennett, Frank Rigo, Don W. Cleveland, Clotilde Lagier-Tourenne, John M. Ravits, Michael W. Baughn
  • METHODS FOR MODULATING C9ORF72 EXPRESSION
    Publication number: 20150267197
    Abstract: Disclosed herein are methods for reducing expression of C90RF72 mRNA and protein in an animal with C90RF72 specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C90RF72 specific inhibitors include antisense compounds. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration C90RF72 specific inhibitors include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), corticalbasal degeneration syndrome (CBD), atypical Parkinsonian syndrome, and olivopontocerellar degeneration (OPCD).
    Type: Application
    Filed: October 15, 2013
    Publication date: September 24, 2015
    Applicants: ISIS PHARMACEUTICALS, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, LUDWIG INSTITUTE FOR CANCER RESEARCH
    Inventors: C. Frank Bennett, Susan M. Freier, Frank Rigo, Don W. Cleveland, Clotilde Lagier-Tourenne, John M. Ravits, Michael W. Baughn